Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Accounts Payables: 2018-2021

Historic Accounts Payables for Black Diamond Therapeutics (BDTX) over the last 2 years, with Sep 2021 value amounting to $4.9 million.

  • Black Diamond Therapeutics' Accounts Payables rose 65.72% to $4.9 million in Q3 2021 from the same period last year, while for Sep 2021 it was $4.9 million, marking a year-over-year increase of 65.72%. This contributed to the annual value of $2.5 million for FY2020, which is 29.23% up from last year.
  • Black Diamond Therapeutics' Accounts Payables amounted to $4.9 million in Q3 2021, which was down 3.40% from $5.0 million recorded in Q2 2021.
  • Black Diamond Therapeutics' 5-year Accounts Payables high stood at $5.0 million for Q2 2021, and its period low was $45,000 during Q2 2020.
  • Moreover, its 3-year median value for Accounts Payables was $3.4 million (2020), whereas its average is $3.2 million.
  • Data for Black Diamond Therapeutics' Accounts Payables shows a peak YoY skyrocketed of 11,077.78% (in 2021) over the last 5 years.
  • Quarterly analysis of 4 years shows Black Diamond Therapeutics' Accounts Payables stood at $416,000 in 2018, then surged by 372.12% to $2.0 million in 2019, then grew by 29.23% to $2.5 million in 2020, then skyrocketed by 65.72% to $4.9 million in 2021.
  • Its Accounts Payables was $4.9 million in Q3 2021, compared to $5.0 million in Q2 2021 and $4.6 million in Q1 2021.